MiR-203a-3p.1 is Involved in the Regulation of Osteogenic Differentiation by Directly Targeting Smad9 in MM-MSCs

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Dec 3

PMID 31788111

Citations 16

Authors

Fang-Yi Fan

Rui Deng

Ling Qiu

Qin Wen

Yunjing Zeng

Li Gao

Chen Zhang

Peiyan Kong

Jiangfan Zhong

Ningyu Zeng

Zhengyu Li

Yi Su

Xi Zhang

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) have emerged as important regulators of bone development and regeneration. The aim of the present study was to determine whether miR-203a-3p.1 is involved in osteogenic differentiation of multiple myeloma (MM)-mesenchymal stem cells (MSCs) and the potential underlying mechanism. MSCs were isolated from patients with MM and normal subjects and confirmed by flow cytometry using specific surface markers. The osteogenic differentiation capacity of MM-MSCs was identified by Alizarin Red S calcium deposition staining and reverse transcription-quantitative PCR (RT-qPCR) of typical osteoblast differentiation markers. The role of miR-203a-3p.1 in the osteoblast differentiation of MM-MSCs was determined by gain or loss of function experiments. The target of miR-203a-3p.1 was identified using bioinformatics (including the miRNA target prediction database TargetScan, miRDB, DIANA TOOLS and venny 2.1.0), luciferase reporter assay, RT-qPCR and western blotting. The expression levels of proteins involved in the Wnt3a/β-catenin signaling pathway were detected by western blot analysis. The results revealed that the osteogenic differentiation capacity of MM-MSCs was reduced when compared with normal (N)-MSCs, as demonstrated by a decrease in calcium deposition and mRNA expression of typical osteoblast differentiation markers, including ALP, OPN and OC. In addition, miR-203a-3p.1 was downregulated in N-MSCs following osteoblast induction, whereas no changes were observed in MM-MSCs. The downregulation of miR-203a-3p.1 resulted in increased osteogenic potential, as indicated by the increase in the mRNA expression levels of the typical osteoblast differentiation markers, including alkaline phosphatase (ALP), osteopontin (OPN) and osteocalcin (OC). Bioinformatics and luciferase reporter assay analysis indicated that mothers against decapentaplegic homolog 9 (Smad9) may be a direct target of miR-203a-3p.1 in N-MSCs. The RT-qPCR and western blot assays revealed that overexpression of smad9 significantly enhanced the effect of miR-203a-3p.1 inhibitors on osteoblast markers, which indicated that miR-203a-3p.1 inhibitors may regulate the osteogenic differentiation of MM-MSCs by upregulating Smad9. In addition, the Wnt3a/β-catenin signaling pathway was activated following miR-203a-3p.1 inhibition. These results suggest that miR-203a-3p.1 may serve an important role in the osteogenic differentiation of MM-MSCs by regulating Smad9 expression.

Citing Articles

Novel_circ_003686 regulates the osteogenic differentiation of MSCs in patients with myeloma bone disease through miR-142-5p/IGF1 axis.

Qiu L, Ma L, Chen D, Zhang N, Cai J, Zhang Q J Bone Oncol. 2023; 43:100509.

PMID: 38021072 PMC: 10654027. DOI: 10.1016/j.jbo.2023.100509.

Osteoblast-Derived Matrix Vesicles Exhibit Exosomal Traits and a Unique Subset of microRNA: Their Caveolae-Dependent Endocytosis Results in Reduced Osteogenic Differentiation.

Skelton A, Cohen D, Boyan B, Schwartz Z Int J Mol Sci. 2023; 24(16).

PMID: 37628952 PMC: 10454939. DOI: 10.3390/ijms241612770.

Comprehensive analysis of epigenetics mechanisms in osteoporosis.

Chen Y, Sun Y, Xue X, Ma H Front Genet. 2023; 14:1153585.

PMID: 37056287 PMC: 10087084. DOI: 10.3389/fgene.2023.1153585.

Timing Expression of miR203a-3p during OA Disease: Preliminary In Vitro Evidence.

Costa V, De Fine M, Raimondi L, Bellavia D, Cordaro A, Carina V Int J Mol Sci. 2023; 24(5).

PMID: 36901745 PMC: 10002134. DOI: 10.3390/ijms24054316.

Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.

Teramachi J, Miki H, Nakamura S, Hiasa M, Harada T, Abe M J Bone Miner Metab. 2023; 41(3):388-403.

PMID: 36856824 PMC: 9975874. DOI: 10.1007/s00774-023-01403-4.

References

Ma X, Li L, Jia T, Chen M, Liu G, Li C . miR-203a controls keratinocyte proliferation and differentiation via targeting the stemness-associated factor ΔNp63 and establishing a regulatory circuit with SNAI2. Biochem Biophys Res Commun. 2017; 491(2):241-249. DOI: 10.1016/j.bbrc.2017.07.131. View

Rodan G, Martin T . Therapeutic approaches to bone diseases. Science. 2000; 289(5484):1508-14. DOI: 10.1126/science.289.5484.1508. View

Zhang J, Fu W, He M, Xie W, Lv Q, Wan G . MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol. 2011; 8(5):829-38. DOI: 10.4161/rna.8.5.16043. View

Yaccoby S . Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol. 2010; 149(3):311-21. PMC: 2864366. DOI: 10.1111/j.1365-2141.2010.08141.x. View

Langenbach F, Handschel J . Effects of dexamethasone, ascorbic acid and β-glycerophosphate on the osteogenic differentiation of stem cells in vitro. Stem Cell Res Ther. 2013; 4(5):117. PMC: 3854789. DOI: 10.1186/scrt328. View

Lopez-Corral L, Gutierrez N, Vidriales M, Mateos M, Rasillo A, Garcia-Sanz R . The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res. 2011; 17(7):1692-700. DOI: 10.1158/1078-0432.CCR-10-1066. View

Vishal M, Vimalraj S, Ajeetha R, Gokulnath M, Keerthana R, He Z . MicroRNA-590-5p Stabilizes Runx2 by Targeting Smad7 During Osteoblast Differentiation. J Cell Physiol. 2016; 232(2):371-380. DOI: 10.1002/jcp.25434. View

Tanaka Y, Nakayamada S, Okada Y . Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy. 2005; 4(3):325-8. DOI: 10.2174/1568010054022015. View

Wang H, Sun W, Ma J, Pan Y, Wang L, Zhang W . Biglycan mediates suture expansion osteogenesis via potentiation of Wnt/β-catenin signaling. J Biomech. 2015; 48(3):432-40. DOI: 10.1016/j.jbiomech.2014.12.032. View

10.

Robey P, Kuznetsov S, Ren J, Klein H, Sabatino M, Stroncek D . Generation of clinical grade human bone marrow stromal cells for use in bone regeneration. Bone. 2014; 70:87-92. PMC: 4268331. DOI: 10.1016/j.bone.2014.07.020. View

11.

Chen E, Zhang W, Ye C, Gao X, Jiang L, Zhao T . Knockdown of SIRT7 enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells partly via activation of the Wnt/β-catenin signaling pathway. Cell Death Dis. 2017; 8(9):e3042. PMC: 5636975. DOI: 10.1038/cddis.2017.429. View

12.

Gregory R, Shiekhattar R . MicroRNA biogenesis and cancer. Cancer Res. 2005; 65(9):3509-12. DOI: 10.1158/0008-5472.CAN-05-0298. View

13.

Pi C, Li Y, Zhou X, Gao B . The expression and function of microRNAs in bone homeostasis. Front Biosci (Landmark Ed). 2015; 20(1):119-38. DOI: 10.2741/4301. View

14.

Raje N, Roodman G . Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res. 2011; 17(6):1278-86. DOI: 10.1158/1078-0432.CCR-10-1804. View

15.

Chen J, Qiu M, Dou C, Cao Z, Dong S . MicroRNAs in Bone Balance and Osteoporosis. Drug Dev Res. 2015; 76(5):235-45. DOI: 10.1002/ddr.21260. View

16.

Hao C, Yang S, Xu W, Shen J, Ye S, Liu X . MiR-708 promotes steroid-induced osteonecrosis of femoral head, suppresses osteogenic differentiation by targeting SMAD3. Sci Rep. 2016; 6:22599. PMC: 4773864. DOI: 10.1038/srep22599. View

17.

Giuliani N, Rizzoli V, Roodman G . Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood. 2006; 108(13):3992-6. DOI: 10.1182/blood-2006-05-026112. View

18.

Guo J, Fei C, Zhao Y, Zhao S, Zheng Q, Su J . Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway. Oncotarget. 2017; 8(33):55405-55421. PMC: 5589668. DOI: 10.18632/oncotarget.19265. View

19.

Tang Y, Zheng L, Zhou J, Chen Y, Yang L, Deng F . miR‑203‑3p participates in the suppression of diabetes‑associated osteogenesis in the jaw bone through targeting Smad1. Int J Mol Med. 2018; 41(3):1595-1607. PMC: 5819914. DOI: 10.3892/ijmm.2018.3373. View

20.

Zhang W, Wu Y, Shiozaki Y, Sugimoto Y, Takigawa T, Tanaka M . miRNA-133a-5p Inhibits the Expression of Osteoblast Differentiation-Associated Markers by Targeting the 3' UTR of RUNX2. DNA Cell Biol. 2018; 37(3):199-209. DOI: 10.1089/dna.2017.3936. View